Northern Trust Corp Boosts Holdings in Kindred Biosciences, Inc. (KIN)
Northern Trust Corp raised its position in Kindred Biosciences, Inc. (NASDAQ:KIN) by 648.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 213,267 shares of the biopharmaceutical company’s stock after purchasing an additional 184,770 shares during the quarter. Northern Trust Corp owned 0.91% of Kindred Biosciences worth $1,834,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. Nationwide Fund Advisors bought a new position in shares of Kindred Biosciences during the second quarter worth about $100,000. JPMorgan Chase & Co. bought a new position in shares of Kindred Biosciences during the second quarter worth about $119,000. Trexquant Investment LP bought a new position in shares of Kindred Biosciences during the second quarter worth about $120,000. State of Wisconsin Investment Board bought a new position in shares of Kindred Biosciences during the second quarter worth about $129,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Kindred Biosciences by 28.5% during the first quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 4,954 shares during the last quarter. Hedge funds and other institutional investors own 66.85% of the company’s stock.
KIN has been the subject of a number of analyst reports. Zacks Investment Research upgraded Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a research report on Wednesday, September 6th. B. Riley restated a “buy” rating and set a $11.00 price objective on shares of Kindred Biosciences in a research report on Monday, November 20th. HC Wainwright initiated coverage on Kindred Biosciences in a research report on Friday, November 17th. They set a “buy” rating and a $9.50 price objective for the company. Finally, ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $9.54.
Kindred Biosciences (NASDAQ:KIN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. equities research analysts anticipate that Kindred Biosciences, Inc. will post -1.18 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/02/northern-trust-corp-boosts-holdings-in-kindred-biosciences-inc-kin.html.
About Kindred Biosciences
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Want to see what other hedge funds are holding KIN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kindred Biosciences, Inc. (NASDAQ:KIN).
Receive News & Stock Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related stocks with our FREE daily email newsletter.